Evaluation of widely used models for predicting BRCA1 and BRCA2 mutations

Journal of Medical Genetics

Volumn 41, Issue 4, 2004, Pages 278-285

  Marroni, F ^a   Aretini, P ^a   D'Andrea, E ^b   Caligo, M A ^a   Cortesi, L ^c   Viel, A ^d   Ricevuto, E ^e   Montagna, M ^b   Cipollini, G ^a   Ferrari, S ^c   Santarosa, M ^d   Bisegna, R ^e   Bailey Wilson, J E ^f   Bevilacqua, G ^a   Parmigiani, G ^g   Presciuttini, S ^a,f,h  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^e UNIVERSITY OF L'AQUILA   (Italy)

^f NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h c/o Centro Retrovirus ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; EVALUATION; EXPERIMENTAL MODEL; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC SCREENING; HUMAN; MALE; MOLECULAR MODEL; ONCOGENE; PERFORMANCE; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC;

EID: 11144356886     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.2003.013623     Document Type: Article

References (38)

1. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995;56:265-71.
2. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Borkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M, and the Breast Cancer Linkage Consortium. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998;62:676-89.
3. Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a papulation-bosed series of breast cancer cases. Br J Cancer 2000;83:1301-8.
4. Bishop DT. BRCA1 and BRCA2 and breast cancer incidence: a review. Ann Oncol 1999;10(suppl 6):113-9.
5. Steel M, Smyth E, Vasen H, Eccles D, Evans G, Moller P, Hodgson S, Stoppa-Lyonnet D, Chang-Claude J, Caligo M, Morrison P, Haites N. Ethical, social and economic issues in familial breast cancer: a compilation of views from the EC Biomed II Demonstration Project. Dis Markers 1999;15:125-31.
6. Edwards RT. Steering a course around the genetic iceberg. J Public Health Med 2001;23:3-4
7. Parmigiani G. Modeling in medical decision making. A bayesian approach. New York: Wiley, 2002.
8. Couch FJ, DeShano ML, Blackwood MA, Calzone K, Stopfer J, Campeau L, Ganguly A, Rebbeck T, Weber BL. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 1997;336:1409-15.
9. Shattuck-Eidens D, Oliphant A, McClure M, McBride C, Gupte J, Rubano T, Pruss D, Tavtiian S, Teng DHF, Adey N, Staebell M, Gumpper K, Lundstrom R, Hulick M, Kelly M, Holmen J, Lingenfelter B, Manley S, Fujumura F, Luce M, Ward B, Cannon-Albright L, Steele L, Offit K, Gilewski T, Norton L, Brown K, Schulz C, Hampel H, Schluger A, Giulotto E, Zoli W, Ravaioli A, Nevanlinna H, Pyrhonen S, Rowley P, Scalia J, Michaelson R, Scottt R, Radice P, Pierotti M, Garber J, Isaacs C, Peshkin B, Lippman M, Dosik M, Caligo M, Greenstein R, Pilarski R, Weber B, Burgemeister R, Frank T, Skolnick M, Thomas A. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 1997;278:1242-50.
10. Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, Gumpper KL, Scholl T, Tavtigian SV, Pruss DR, Critchfield GC. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002;20:1480-90.
11. de la Hoya M, Osorio A, Godino J, Sulleiro S, Tosar A, Perez-Segura P, Fernandez C, Rodriguez R, Diaz-Rubio E, Benitez J, Devilee P, Caldes T. Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing. Int J Cancer 2002;97:466-71.
12. Vahteristo P, Eerola H, Tamminen A, Blomqvist C, Nevanlinna H. A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families. Br J Cancer 2001;84:704-8.
13. Claus EB, Risch N, Thompson WD. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 1991;48:232-42.
14. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 1994;73:643-51.
15. Claus EB, Risch N, Thompson WD. The calculation of breast cancer risk for women with a first degree family history of ovarian cancer. Breast Cancer Res Treat 1993;28:115-20.
16. Berry DA, Parmigiani G, Sanchez J, Schildkraut J, Winer E. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst 1997;89:227-38.
17. Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 1998;62:145-58.
18. Schaffer AA. Faster linkage analysis computations for pedigrees with loops or unused alleles. Hum Hered 1996;46:226-35.
19. Osorio A, Barroso A, Martinez B, Cebrian A, San Roman JM, Lobo F, Robledo M, Benitez J. Molecular analysis of the BRCA1 and BRCA2 genes in 32 breast and/or ovarian cancer Spanish families. Br J Cancer 2000;82:1266-70.
20. Martin AM, Blackwood MA, Antin-Ozerkis D, Shih HA, Calzone K, Colligon TA, Seal S, Collins N, Stratton MR, Weber BL, Nathanson KL. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic. J Clin Oncol 2001;19:2247-53.
21. Shih HA, Couch FJ, Nathanson KL, Blackwood MA, Rebbeck TR, Armstrong KA, Calzone K, Stopfer J, Seal S, Stratton MR, Weber BL. BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic. J Clin Oncol 2002;20:994-9.
22. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Sea S, Tran T, Averill D, Fields P, Marshall G, Narod S, Lenoir GM, Lynch H, Feunteun J, Devilee P, Cornelisse CJ, Menko FH, Daly PA, Ormiston W, McManus R, Pye C, Lewis CM, Cannon Albright L, Peto J, Ponder BAJ, Skolnick MH, Easton DF, Goldgar DE, Stratton MR. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994;265:2088-90.
23. Malone KE, Daling JR, Neal C, Suter NM, O'Brien C, Cushing-Haugen K, Jonasdottir TJ, Thompson JD, Ostrander EA. Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer 2000;88:1393-402.
24. Aretini P, D'Andrea E, Pasini B, Viel A, Costantini RM, Cortesi L, Ricevuto E, Agata S, Bisegna R, Boiocchi M, Caligo MA, Chieco-Bianchi L, Cipollini G, Crucianelli R, D'Amico C, Federico M, Ghimenti C, De Giacomi C, De Nicolo A, Della Puppa L, Ferrari S, Ficorella C, Iandolo D, Manoukian S, Marchetti P, Marroni F, Menin C, Montagna M, Ottini L, Pensotti V, Pierotti M, Radice P, Santarosa M, Silingardi V, Turchetti D, Bevilacqua G, Presciuttini S. Different expressivity of BRCA1 and BRCA2: analysis of 179 Italian pedigrees with identified mutation. Breast Cancer Res Treat 2003;81:71-9.
25. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 2002;20:2701-12.
26. Euhus DM, Smith KC, Robinson L, Stucky A, Olopade OI, Cummings S, Garber JE, Chittenden A, Mills GB, Rieger P, Esserman L, Crawford B, Hughes KS, Roche CA, Ganz PA, Seldon J, Fabian CJ, Klemp J, Tomlinson G. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst 2002;94:844-51.
27. Shannon KM, Lubratovich ML, Finkelstein DM, Smith BL, Powell SN, Seiden MV. Model-based predictions of BRCA1/2 mutation status in breast carcinoma patients treated at an academic medical center. Cancer 2002;94:305-13.
28. De la Hoya M, Diez O, Perez-Segura P, Godino J, Fernandez JM, Sanz J, Alonso C, Baiget M, Diaz-Rubio E, Caldes T. Pre-test prediction models of BRCA1 or BRCA2 mutation in breast/ovarian families attending familial cancer clinics. J Med Genet 2003;40:503-10.
29. Love RR, Evans AM, Josten DM. The accuracy of patient reports of a family history of cancer. J Chronic Dis 1985;38:289-93.
30. Frank TS, Manley SA, Olopade OI, Cummings S, Garber JE, Bernhardt B, Antman K, Russo D, Wood ME, Mullineau L, Isaacs C, Peshkin B, Buys S, Venne V, Rowley PT, Loader S, Offit K, Hampel H, Brener D, Winer EP, Clark S, Weber B, Strong LC, Reiger P, McClure M, Ward B, Shattuck-Eidens D, Oliphant A, Skolnick MH, Thomas A. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 1998;16:2417-25.
31. Basham VM, Lipscombe JM, Ward JM, Gayther SA, Ponder BA, Easton DF, Pharoah PD. BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast Cancer Res 2002;4:R2.
32. Eng C, Brody LC, Wagner TM, Devilee P, Vijg J, Szabo C, Tavtigian SV, Nathanson KL, Ostrander E, Frank TS. Interpreting epidemiological research: blinded comparison of methods used to estimate the prevalence of inherited mutations in BRCA1. J Med Genet 2001;38:824-33.
33. DeGroot MH FS. Assessing probability assessors: calibration and refinement. Statistical decision theory and related topics III 1982;1:291-314.
34. Cox DR, Snell EJ. Analysis of binary data. London, New York, Tokyo, Melbourne, Madras: Chapman and Hall, 1989:41-3.
35. Iversen E, Parmigiani G, Berry D. Validating Bayesian prediction models: a case study in genetic susceptibility to breast cancer. Case studies in Bayesian statistics 1998;IV:321-38.
36. American Society of Clinical Oncology. Policy statement: genetic testing for cancer susceptibility (approved February 20, 1996) Recommendations pertaining to clinical aspects of genetic testing for cancer susceptibility. Alexandria: ASCO, 2002.
37. Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 1995;57:1457-62.
38. Ottini L, D'Amico C, Noviello C, Lauro S, Lalle M, Fornarini G, Colantuoni OA, Pizzi C, Cortesi E, Carlini S, Guadagni F, Bianco AR, Frati L, Contegiacomo A, Mariani-Costantini R. BRCA2 and BRCA2 mutations in central and southern Italian patients. Breast Cancer Res 2000;2:307-10.